AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Zacks Investment Research on MSN5d
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyViking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...
Zacks Investment Research on MSN4d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback